NEJM July 2026 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

This Week In Medicine · Aug 4, 2026 · 1m

This study evaluates the effectiveness of teclistamab, a specialized bispecific antibody, as an early treatment option for patients facing a relapse of multiple myeloma. By comparing this novel therapy against standard clinical drug combinations, researchers found that teclistamab significantly extended progression-free survival and resulted in a dramatically higher rate of complete disease response. While the treatment demonstrated superior efficacy in slowing cancer growth and improving overall survival, it also presented a higher risk of serious infections and unique immune-related side…